The antibody recognizes and permanently binds to a radioactive carrier or other therapeutically active molecule and forms a permanent chemical bond, which can deliver the maximum amount of therapy directly to a tumor cell, while sparing healthy tissue. • Microbiotix Inc., of Worcester, Mass., received exclusive worldwide rights to license a series of proprietary antiviral compounds from Nissin Food Products Co...It is developing other biopharmaceutical products. • SkyePharma plc, of London

Genopoietic has manufactured the vector for these treatments. • BioErgonomics Inc., of St. Paul, Minn., and Loma Linda University Medical Center entered an agreement granting BioErgonomics an option to acquire an exclusive license to commercialize certain new technology covered under the center’s patent rights for “Iron Regulating Protein–2 as a Diagnostic for Alzheimer’s Disease and Other Neurodegenerative Diseases.” Financial details were not disclosed...They intend to adapt deCode’s genotyping

Spiegelmers are invulnerable to enzymes, Noxxon said, adding that it intends spiegelmers to be the next generation of high-affinity, high-specificity biological tools improving on small molecules, antibodies and traditional RNA and DNA oligonucleotides. • MorphoSys AG, of Martinsried, Germany, said its ongoing collaboration with Bayer AG, of Leverkusen, Germany, was extended for an additional four years...The grant is expected to fuel research on potential new drugs designed to trigger apoptosis

That refusal forced Scotia to apply for an administration order to enable the company to carry on trading and eke out its resources until it could submit an appeal...eye-care company, to explore novel approaches to treating glaucoma

Cipher has licensed two other products from Galephar, and said it expects to file similar INDs to begin their clinical programs in the near future. • Celgene Corp., of Warren, N.J., said preclinical studies of its JNK (c-Jun N-terminal kinase) inhibitor, SP600125, in inflammatory cells associated with rheumatoid arthritis, indicate that JNK activation is a primary mediator of joint destruction in arthritis...The clinicians later injected the carrier molecule and isotope, which then attached to the

Immunogen plans to license MorphoSys’ HuCAL. (Human Combinatorial Antibody Library) technology to generate antibodies for research purposes...SRP299 was also successful in a Phase II trial in children with moderate to severe atopic dermatitis, and SR Pharma says it is planning further trials in parallel with the asthma program. • Xenova Group plc, of Slough, UK, will cut 45 jobs after a strategic review following the merger with Cantab Pharmaceuticals plc

Bayer plans to submit a new drug application for vardenafil later this year. • BioMarin Pharmaceutical Inc., of Novato, Calif., filed a clinical trial exemption application with the Medicines Control Agency in the United Kingdom for permission to conduct human clinical trials of Vibriolysin Topical in patients with serious burns...Ltd., of Tokyo, signed a five-year subscription agreement, giving it access to the Celera Discovery System and use of Celera’s database products, bioinformatics systems

Cephalon plans to use the proceeds for working capital and general corporate purposes. (See BioWorld Today, May 3, 2001.) • Drug Royalty Corp...The offering is expected to close on June 26...The software allows researchers to visualize and isolate genetic fragments that have been robotically arrayed on nylon membranes and other surfaces

The other software module, pathSCOUT, enables researchers to analyze metabolic pathways in silico. • Astex Technology Ltd., of Cambridge, UK, a drug discovery company specializing in high-throughput X-ray crystallography, has joined a consortium run by the bioinformatics company Global Phasing Ltd., which has developed software programs for converting X-ray crystallography data into 3-D structures of macromolecules...The first patent relates to a method for in vitro production of bone, the second

Amgen submitted data to the FDA seeking approval for Kineret in December 1999 and additional data in April...They plan to conduct further single-agent trials, combination studies with pegylated interferon and ribavirin, and longer-term dosing trials. • Lilly ICOS LLC, a joint venture of ICOS Corp., of Bothell, Wash., and Eli Lilly and Co., of Indianapolis, said results of an exploratory placebo-controlled trial of IC351 showed no conclusive treatment effect relative to placebo in women with female

November will get DM1.1 million of the grant. • Schwarz Pharma AG , of Monheim, Germany, and Genentech Inc., of South Francisco, signed an agreement under which Genentech reacquired the exclusive development and marketing rights to NutropinAq and NutropinDepot recombinant human growth hormone products in Europe and certain other countries outside the United States, Canada, China and Japan...The company last week also said that growth hormones no longer fit Schwarz Pharma’s business plan as it

CAT-213 is designed to inhibit the major stimulus that draws eosinophils, a type of white blood cell, to tissues. • Cephalon Inc., of West Chester, Pa., granted Australian and New Zealand sales, marketing and distribution rights for Actiq (oral transmucosal fentanyl citrate) to Orphan Australia Pty...The collaboration will attempt to develop one-molecule drugs and extend clinical studies to in vivo experiments in animal models simulating Alzheimer’s disease, develop a diagnostic for

The agreements relate to the bacterial expression of antibodies...BioTransplant will use proceeds from the offering to advance its immune modulation therapy programs, including the AlloMune family of products, in addition to developing and commercializing its Eligix Cell Separation Systems. (See BioWorld Today, June 8, 2001.) • BioVex Ltd., of London, entered two evaluation agreements with Aventis Pharma AG, of Frankfurt, Germany...The group committed to a total investment of up to $130 million, most

Each note will convert at the holder’s option to CTI common stock at an initial conversion price of $34 per share...CTI said it will use proceeds from the offering to fund clinical trials, expand its sales and marketing capabilities, potential acquisitions and general corporate purposes. (See BioWorld Today, June 6, 2001.) • Genentech Inc., of South San Francisco, reacquired rights from Schwarz Pharma AG, of Monheim, Germany, to two growth hormone products

However, Cytomyx set out to raise up to £3 million, and £1.45 million was already committed in a prefunding round...Vetter said RAISE is expected to enhance early steps of drug discovery 100-fold

The grant is to fund the development of antibodies to prevent the transmission of human papillomavirus. • Gilead Sciences Inc., of Foster City, Calif., said in vitro data characterizing the resistance profile of tenofovir disoproxil fumarate (tenofovir DF), the company’s potential HIV therapeutic, indicated that reduced susceptibility to tenofovir is infrequent and not closely correlated with cross-resistance to commercially available nucleoside reverse transcriptase inhibitor or non-nucleoside

As part of the proposed settlement, Anika will pay a total of $1.25 million into a settlement fund that will, among other things, be used to pay people who purchased or otherwise acquired Anika common stock between April 15, 1998, and May 30, 2000...MyoCell is designed to regenerate damaged heart muscle tissue through the transplantation of immature muscle cells...Those trials are expected to be completed in December

The addition to the Biotechnology Innovation Fund, designed to assist start-up biotech companies in advancing to proof-of-concept stage, was announced recently as part of the annual federal budget statement...Noxxon Pharma AG, of Berlin, expanded its management board

The randomized, double-blinded, placebo-controlled study is designed to investigate the efficacy and safety of the Femprox cream in approximately 110 pre-menopausal women diagnosed with the disorder. • Octagen Corp., of Bala Cynwyd, Pa., entered a collaboration with the University of Minnesota to develop gene therapy technology for treatment of hemophilia A and other genetically based diseases...Access to the company’s gene cloning and drug development platforms now is available through a secure